Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen John Yarwood has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and Evaluation of Benzofuran Oxoacetic Acid Compounds as EPAC1 Activators

    by David Morgan, Jolanta Wiejak, Frederick G. Powell, Chiara Fitzpatrick, Stephen J. Yarwood, Graeme Barker

    Exchange protein directly activated by cAMP 1 (EPAC1) modulates Rap signaling and fibrosis. We report benzofuran oxoacetic acids as non-nucleotide EPAC1 agonists. Convergent synthesis delivered C2-diversified analogues (overall yields ≈ 3-7%). Fluorescent competition at isolated CNBDs mapped isoform engagement: several analogues favored EPAC1 (e.g., DM244, DM357, and DM408), DM312 favored EPAC2, and small C2 changes tuned bias. In cells, EPAC1-transfected U2OS assays showed significant Rap1-GTP increases for DM243, DM244, and DM245, with no activation in EPAC2 cells and no detectable protein kinase A activity. In disease-relevant contexts, the series attenuated IL-6/STAT3 signaling in human umbilical vascular endothelial cells and inhibited TGF-β1-induced fibroblast-to-myofibroblast transition (αSMA, Collagen I) with midmicromolar potencies; known drugs, SB525334 and nintedanib, remained more potent, yet nintedanib was markedly more cytotoxic. Across assays, some binding-phenotype disconnects emerged, plausibly reflecting exposure, signaling bias, and cell-context effects. Overall, benzofuran oxoacetic acids provide EPAC-pathway probes with a favorable tolerability window and scope for potency optimization as antifibrotics.


  • Open Access

    Development and Evaluation of Benzofuran Oxoacetic Acid Compounds as EPAC1 Activators

    by David Morgan, Jolanta Wiejak, Frederick Powell, Chiara Fitzpatrick, Stephen Yarwood, Graeme Barker

    Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical guanine nucleotide exchange factor that transduces cAMP signals to Rap GTPases, controlling pathways implicated in inflammation and fibrosis. Here, we report the design, synthesis, and biological evaluation of a novel series of benzofuran oxoacetic acid derivatives as selective EPAC1 agonists. A convergent synthetic route enabled late‐stage diversification at the benzofuran C2 position, yielding analogues in 3–7% overall yield despite challenges in reduction and oxidation steps. Structural modifications at C3 proved incompatible with the required reductive cyclization, whereas aryl ketone substitutions at C2 generated the most potent compounds. Biochemical characterization demonstrated that several analogues, notably DM243, DM245, and DM312, activate EPAC1 with complete selectivity over EPAC2 and no detectable Protein Kinase A activation. DM243 induced Rap1•GTP formation in EPAC1‐expressing cells to levels comparable to cyclic nucleotide benchmarks. In cellular assays, these compounds inhibited IL-6-driven JAK/STAT3 signalling and suppressed TGF-β1–induced fibroblast‐to‐myofibroblast transition (FMT), reducing α-smooth muscle actin and Collagen I expression with potencies rivalling the anti-fibrotic drug, nintedanib, yet exhibiting lower cytotoxicity, determined by nuclei count. Structure–activity relationship analysis revealed that C2 aryl ketone substituents enhance EPAC1 binding and functional efficacy, while subtle steric and electronic variations modulate isoform specificity. This work establishes benzofuran oxoacetic acids as a new chemotype for isoform‐selective EPAC1 activation. Our findings highlight the translational potential of targeted EPAC1 agonists as anti‐inflammatory and anti‐fibrotic agents in diseases driven by dysregulated cAMP signalling.

  • Open Access

    Selective EPAC1 activators enhance endothelial function in models of vascular inflammation

    by Neil MacRitchie, Danila Gurgone, Jolanta Wiejak, Graeme Barker, Paul Burgoyne, Frank Lezoualc’h, Pasquale Maffia, Stephen J. Yarwood


  • Open Access

    Elucidation of the Mechanism of PartialActivation of EPAC1 Allosteric Modulators byMarkov State Modelling

    by Adele Hardie, Frederick Powell, Silvia Lovera, Stephen Yarwood, Graeme Barker, Julien Michel

    The development of selective modulators of exchange protein activated by cAMP (EPAC1/RAPGEF3), which preferentially bind its cAMP-binding site, would pave the way for novel therapeutic interventions in cardiac, metabolic, inflammatory, and oncologic disorders. Here we have applied a computational workflow using Markov State Models (MSMs) and steered molecular dynamics (sMD) to probe the allosteric activation of EPAC1 by both cAMP and pharmaceutical hit compound I942. sMD was used to examine the large-scale domain rearrangement EPAC1 undergoes during activation. Intermediate conformations accessed via sMD were then used as starting points for equilibrium MD simulations, which were pooled for the construction of MSMs. The resulting models capture the activation of wild-type (WT) EPAC1 by cAMP, and provide an explanation for the lack of response to cAMP shown by the L273W point mutant. sMD/MSM modelling also elucidated the structural basis for partial activation of EPAC1 by ligand I942 and revealed the crucial contribution of ligand interactions with EPAC1’s catalytic region to achieve full activation. The mechanistic insights from this study suggest a design strategy to guide the development of potent small-molecule EPAC1 activators.

  • Open Access

    Vascular smooth muscle cells enhance immune/vascular interplay in a 3-cell model of vascular inflammation

    by Jolanta Wiejak, Fiona A. Murphy, Pasquale Maffia, Stephen J. Yarwood

    Atherosclerosis is a serious cardiovascular disease that is characterised by the development of atheroma, which are lipid-laden plaques that build up within arterial walls due to chronic inflammatory processes. These lesions are fundamentally attributed to a complex cellular crosstalk between vascular smooth muscle cells (VSMCs), vascular endothelial cells (VECs) and central immune cells, such as macrophages (Mɸs), which promote vascular inflammation. The presence of VSMCs exerts both positive and negative effects during atheroma development, which can be attributed to their phenotypic plasticity. Understanding the interactions between these key cell types during the development of vascular inflammation and atheroma will enhance the scope for new therapeutic interventions. This study aims to determine the importance of VSMCs for shaping the extracellular cytokine/chemokine profile and transcriptional responses of VECs (human coronary artery endothelial cells; HCAECs) to activated lipopolysaccharide (LPS)-stimulated THP1 Mɸs, in a 3-cell model of human vascular inflammation. It is evident that within the presence of VSMCs, enhanced cytokine production was associated with up-regulation of genes associated with vascular inflammation t. Results demonstrate that the presence of VSMCs in co-culture experiments enhanced cytokine production (including CXCL1/GROα, IL-6, IL-8 and CCL2/MCP1) and inflammatory gene expression (including genes involved in JAK/STAT, Jun and NFκB signalling) in HCAECs co-cultured with LPS-stimulated THP1 Mɸs. Our results highlight the importance of VSMCs in immune/endothelial cell interplay and indicate that 3-cell, rather than 2-cell co-culture, may be more appropriate for the study of cellular crosstalk between immune and vascular compartments in response to inflammatory and atherogenic stimuli.


  • Open Access

    Protein interaction, cytotoxic, transcriptomic and proteomic responses to structurally distinct EPAC1 activators in HUVECs

    by Jolanta Wiejak, Urszula Luchowska-Stańska, Pingyuan Wang, Jia Zhou, Pasquale Maffia, David Morgan, Graeme Barker, Stephen J. Yarwood

    The N-acylsulfonamide derivative, I942, represents the first non-cyclic nucleotide partial agonist of EPAC1. This was soon followed by the identification of the I942 analogues, PW0381, PW0521 and PWO577 and a series of benzofuran oxoacetic acid EPAC1 activators, SY006, SY007 and SY009. Protein interaction, cytotoxicity and EPAC1 activation assays applied here identify PWO577 and SY007 as being effective EPAC1 binders that are well tolerated in HUVECs at concentrations greater than 100 μM and up to 48 h incubation and are effective activators of transfected EPAC1 in U2OS cells. Using RNAseq in HUVECs we show that PWO577 and SY007 regulate approximately 11,000 shared genes, with only few differential gene changes being “off-target”. The genes significantly regulated by both PWO577 and SY007 included a subset of genes normally associated with endothelial activation, including ICAM1, MMP1 and CCL2. Of these, only the expression of MMP1 was markedly increased at the protein level, as determined by LC–MS-based proteomics. Both PWO577 and SY007 suppressed IL-6-induced STAT3 activation and associated downstream gene expression, including inhibition of SOCS3, STAT3, IL6ST and JAK3 genes. Together these results demonstrate the utility of structurally distinct, specific and non-toxic EPAC1 activators. Future modifications will be aimed at eliminating the few noted off-target effects.


  • Open Access

    Identification and Characterization of an Affimer Affinity Reagent for the Detection of the cAMP Sensor, EPAC1

    by Hanna K. Buist, Urszula Luchowska-Stańska, Boy van Basten, Jessica Valli, Brian O. Smith, George S. Baillie, Colin Rickman, Bryon Ricketts, Alex Davidson, Ryan Hannam, et al.

    An exchange protein directly activated by cAMP 1 (EPAC1) is an intracellular sensor for cAMP that is involved in a wide variety of cellular and physiological processes in health and disease. However, reagents are lacking to study its association with intracellular cAMP nanodomains. Here, we use non-antibody Affimer protein scaffolds to develop isoform-selective protein binders of EPAC1. Phage-display screens were carried out against purified, biotinylated human recombinant EPAC1ΔDEP protein (amino acids 149–811), which identified five potential EPAC1-selective Affimer binders. Dot blots and indirect ELISA assays were next used to identify Affimer 780A as the top EPAC1 binder. Mutagenesis studies further revealed a potential interaction site for 780A within the EPAC1 cyclic nucleotide binding domain (CNBD). In addition, 780A was shown to co-precipitate EPAC1 from transfected cells and co-localize with both wild-type EPAC1 and a mis-targeting mutant of EPAC1(K212R), predominantly in perinuclear and cytosolic regions of cells, respectively. As a novel EPAC1-selective binder, 780A therefore has the potential to be used in future studies to further understand compartmentalization of the cAMP-EPAC1 signaling system.


  • Open Access

    Recent Developments in C−H Functionalisation of Benzofurans and Benzothiophenes

    by David Morgan, Stephen J. Yarwood, Graeme Barker

    Benzofurans and benzothiophenes are important pharmaceutical motifs, appearing in a broad range of small molecule therapeutic classes. Often overlooked by synthetic methodologists in favour reactions of the analogous indole bicyclic system, there is nevertheless a plurality of approaches to effecting benzofuran and benzothiophene C−H functionalisations. In this review, we summarise progress in this area over the past five years, including 1) alkylations, 2) arylations and heteroarylations, 3) carboxylations, carbamoylations, and C‐heteroatom bond formations and 4) cyclisations.


  • Open Access

    Special Issue on “New Advances in Cyclic AMP Signalling”—An Editorial Overview

    by Stephen John Yarwood

    The cyclic nucleotides 3′,5′-adenosine monophosphate (cyclic AMP) signalling system underlies the control of many biological events and disease processes in man. Cyclic AMP is synthesised by adenylate cyclase (AC) enzymes in order to activate effector proteins and it is then degraded by phosphodiesterase (PDE) enzymes. Research in recent years has identified a range of cell-type-specific cyclic AMP effector proteins, including protein kinase A (PKA), exchange factor directly activated by cyclic AMP (EPAC), cyclic AMP responsive ion channels (CICs), and the Popeye domain containing (POPDC) proteins, which participate in different signalling mechanisms. In addition, recent advances have revealed new mechanisms of action for cyclic AMP signalling, including new effectors and new levels of compartmentalization into nanodomains, involving AKAP proteins and targeted adenylate cyclase and phosphodiesterase enzymes. This Special Issue contains 21 papers that highlight advances in our current understanding of the biology of compartmentlised cyclic AMP signalling. This ranges from issues of pathogenesis and associated molecular pathways, functional assessment of novel nanodomains, to the development of novel tool molecules and new techniques for imaging cyclic AMP compartmentilisation. This editorial aims to summarise these papers within the wider context of cyclic AMP signalling.